CTI Clinical Trial & Consulting Services Announces Formation of Swedish Canadian Subsidiaries and Office
[Cincinnati, OH ~ November 5, 2015]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that it has opened an office in Stockholm, Sweden. The office is opened through the wholly-owned subsidiary, Clinical Trial and Consulting Services Sweden AB. The company has opened more than a dozen offices over the past few years, with additional international expansion planned for 2016.
“We have been conducting studies in Sweden with our own staff for many years, and felt that our international growth necessitated a physical presence in the country to better serve our pharmaceutical and biotechnology clients,” states Patrick Earley, Vice President, International.
Additionally, the company has started a wholly-owned subsidiary in Canada, CTI Clinical Trial & Consulting Services Canada ULC, with plans for an office in the future. According to Earley, “This new subsidiary shows CTI’s commitment to the high quality of research in Canadian hospitals and universities, as well as enables our sponsors to take advantage of research tax incentives that are provided by the government.”
CTI has been working for seventeen years in the drug development industry across North America, Europe, South America, Pac-Asia, and Africa, specializing in clinical research programs involving critically ill patient populations, and has more than 25 offices worldwide to serve nearly 100 pharmaceutical, biotechnology, and medical device clients.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
